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Scale (KPS), Spitzer QOL-Index, Expanded Disability Status Scale (EDSS), and the 
Hamilton Rating Scale for Depression (HAM-D) were evaluated in terms of: concep-
tual framework; patient, literature and clinician contribution to development; process 
for deriving items; content validity; item reduction; linguistic and cultural adaptation; 
scoring; and reliability, validity, and ability to detect change. RESULTS: The FDA 
discourages the use of CROs for symptoms that can only be known to the patient, 
whereas clinical signs are usually observed and interpreted by the clinician. Despite 
the widespread use of the KPS as a classiﬁcation of functional status in patients with 
cancer, there is little data supporting the development, content validity, and statistical 
measurement properties of the scale. Among other critiques, the EDSS has question-
able inter-rater reliability. Although the Spitzer QOL-index was developed with 
patient input and has documented measurement properties, the use of proxy for QOL/
HRQL evaluations is widely discouraged. The HAM-D is considered the ‘gold stan-
dard’ of depression rating scales with good psychometric properties, but with ques-
tionable content validity. CONCLUSIONS: The suitability of the selected CROs as 
endpoints for regulatory approvals varied widely. CROs are essential and complimen-
tary primary and secondary endpoints for drug evaluations for the purpose of FDA 
regulatory submissions, it is likely that sponsors will face increasing FDA scrutiny of 
CRO endpoints for the purpose of label claims.
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OBJECTIVES: To compare the ways pharmacoeconomic (PE) guidelines in European 
and North American countries deﬁne the societal perspective for economic evalua-
tions. METHODS: Full-text country-speciﬁc PE guidelines were obtained via the 
ISPOR website and where possible cross-referenced with Health Technology Assess-
ment (HTA) agency recommendations. The following countries were selected for 
comparison: Belgium, Canada, Finland, France, Italy, Norway, the The Netherlands, 
Portugal and Sweden. The cost categories considered for the societal perspective were 
assessed and compared between country guidelines. RESULTS: PE guidelines from 
eight of the selected countries identiﬁed speciﬁc cost categories for the societal perspec-
tive. Guidelines agreed that the direct costs associated with this perspective included 
costs to the health service, costs to other publicly funded services and costs to patients/
family. Costs of time lost by family/unpaid carers was considered by 6/8 guidelines, 
which differed in assigning the cost as direct or indirect. There were differences in the 
indirect costs considered; costs of time lost by patients was only considered by 2/8 
guidelines. Intangible costs were considered by 4/8 guidelines, although it was gener-
ally accepted that these should be accounted for in the outcome measurement rather 
than through costs. Productivity loss was considered as an indirect cost by nine 
guidelines; however the preferred method of derivation differed between guidelines: 
2/9 guidelines preferred the Friction Cost Method (FCM) and 3/9 guidelines preferred 
the Human Capital Method (HCM). Moreover, there were differing views regarding 
the types of productivity loss to include: Portugal recommended consideration of 
employee-related loss only, whereas Canada also included loss to the employer associ-
ated with hiring new staff. CONCLUSIONS: There are subtle differences between the 
ways the societal perspective is deﬁned by PE guidelines in Europe and North America. 
This should be considered when devising evidence generation activities to support 
economic modelling, and may ultimately impact the outcome of HTA decisions.
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INTRODUCTION: Number needed to treat/harm (NNT/NNH) values are universally 
understood and applied by clinical decision makers. Therefore providing these values 
alongside cost effectiveness analysis (CEA) results may increase the relevance and 
clarify clinical implications of CEAs to decision makers. OBJECTIVES: To review the 
literature of CEA studies that incorporate NNT/NNH values. METHODS: We 
searched Pub Med using the Mesh term “cost-beneﬁt analysis” and “number needed 
to treat “, “number needed to harm”, “NNT”, or “NNH”. We included CEA studies 
and studies describing relationships between NNT/NNH and quality adjusted life 
years (QALYs) published in English. RESULTS: There were 102 publications identi-
ﬁed. Of these 47 provided both CEA and NNT/NNH results. There were 43 (91.5%) 
studies published in clinician-focused practice journals, 2 (4.3%) in policy journals, 
and 2 (4.3%) in economic journals. The CEA incorporated NNT/NNH directly as 
part of the CEA ratio in 23 (48.9%) studies and CEA was separately stated from 
NNT/NNH in 14 (29.8%) studies. The CEA was expressed as cost per QALY dis-
tinctly from NNT/NNH in 10 (21.3%). The focuses of the articles were disease 
treatments in 28 (59.5%) studies, disease prevention in 15 (31.9%), and patient educa-
tion or disease management in 2 (4.3%) each. Also, there were 4 studies regarding 
relationships between NNT/NNH and QALYs. CONCLUSIONS: We found that the 
majority of articles incorporating NNT/NNH into CEA were published in clinical 
practice journals and most involved comparisons of speciﬁc disease treatments. Incor-
porating NNT/NNH into CEA results may improve relevance to clinical decision-
making, but further research is needed regarding how they are best integrated. One 
alternative may include weighting NNT/NNH values for different outcomes in terms 
of QALYs.
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OBJECTIVES: One of the chronic issues in pharmaceutical utilization management is 
the dearth of accurate price benchmarks available to establish pharmacy-pricing 
performance. This paucity of appropriate benchmarks is further complicated for 
organizations, such as TRICARE, who have reason to believe that their demographics 
and hence disease proﬁles yield atypical prescription drug market baskets. Thus, to 
obtain an accurate assessment of organizational performance, organization-speciﬁc 
indices need to be developed. METHODS: A unique approach to developing organiza-
tion speciﬁc benchmarks is underway in a joint venture between the TRICARE 
Pharmaceutical Operations Directorate (POD) and the US Bureau of Labor Statistics 
(BLS). The primary method is to match retail pricing information provided by BLS 
and portfolio information provided by TRICARE to construct organization speciﬁc 
benchmarks that can be tracked over time. Variables from the Consumer Price Index 
for Prescription Drugs (CPI-Rx) are transferred to the POD as speciﬁed in an inter-
governmental memorandum of understanding. To form an overall TRICARE-Rx 
index for a speciﬁc month, all TRICARE prescription data are aggregated by speciﬁc 
drug and the number of prescriptions is computed for each drug for speciﬁc month 
using a ﬁle extracted from the Pharmacy Data Transaction Service (PDTS). CPI-Rx 
prices are then aggregated by same list of unique drugs used in the TRICARE sample 
then averaged in a separate ﬁle. The ﬁles are then merged using NDC codes as the 
key. The index is computed using the average CPI-Rx price for each speciﬁc drug 
multiplied by the TRICARE N for the corresponding drugs then averaged. CONCLU-
SIONS: TRICARE spends roughly $7.5 Billion annually for prescription drugs. With 
the development of these indices, we can better gauge our cost containment priorities 
and efforts. This will help us determine if increases in costs are due to general drug 
price inﬂation speciﬁc to our unique market basket of drugs.
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OBJECTIVES: Commercial software can be expensive when conducting pharmaco-
economic analyses. We developed a free web-based software program, which incor-
porates Markov transition probabilities to compare the cost-effectiveness of any two 
treatments. The web-based software program was based on the model described in a 
decision modeling for health economic evaluation textbook, edited by A. Briggs. This 
Markov web-based software program calculates the incremental cost-effectiveness 
based on Markov matrices using multi-state transition probabilities, along with cor-
responding Markov state costs and utilities and graphically displays the results, using 
JavaScript algorithms and is available free at www.healthstrategy.com. The variable 
inputs for two treatment options include state transition probabilities, number of 
cycles, cost per state, and utility per state. The software creates a plot of incremental 
costs versus incremental utilities in cost-effectiveness quadrants; and with death as an 
absorbing state, also graphs life expectancy curves for two treatment comparisons. 
The objective of this study was to validate this free web-based software. METHODS: 
The Excel spreadsheet structure and data downloaded from the web for the speciﬁc 
example described in the modeling textbook were used as the reference case. 
RESULTS: For the example used, considering four transition states for each therapy 
option, and 20 cycles with no discounting, the MS Excel spreadsheet model versus 
the web-based JavaScript software compared as follows: average incremental US dollar 
costs: ($67701 vs. $67853), average incremental utility: (5.89 vs. 5.90) and average 
incremental cost-effectiveness ratio:($11500 vs. $11494). CONCLUSIONS: This free 
web-based Markov matrix JavaScript program gives similar results as the MS Excel 
spreadsheet model. With this free software, the user can input their own therapy 
parameters, and generate incremental costs, incremental utilities, life expectancy 
curves, and incremental cost effectiveness ratios. This free web-based software has 
potential beneﬁt as an educational tool for students and health professionals interested 
in exploring these analytical approaches.
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BACKGROUND: Patient-centered professional practice and technology assessment 
research performed in health professional schools’ clinical simulation centers is a novel 
concept. Opportunities can be created for multidisciplinary collaboration relative to 
evaluation of medication regimen and device complexity. Micro-level costs can then 
be assigned and economic analysis conducted in a more precise fashion than in tradi-
tional clinical trials or database outcomes analysis. METHODS: One university’s 
pharmacy and nursing schools’ clinical simulation centers were used in two separate 
projects to conduct time-and-motion and activity-based costing analyses speciﬁc to 
